Budesonide Prophylaxis for Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after
transplant reduces engraftment fever in autologous and allogeneic stem cell transplant
recipients.